S&P 500   4,076.57
DOW   34,395.01
QQQ   293.72
Is Apple Going To Rally Into Year End?
The Small Biotech Scaring Big Pharma (Ad)
25 Ways to Improve Your Financial Situation in 1 Hour
La-Z-Boy Reclines To More Comfortable Levels 
5 Hypergrowth Stocks to Own in 2023 (Ad)pixel
Are the Short Sellers Still Right About Mullen Automotive stock? 
Is The Recovery Rally Here For SoFi?
5 Hypergrowth Stocks to Own in 2023 (Ad)pixel
Biden administration presses senators to avert rail strike
Trump Org. defense lawyer scolded for using struck testimony
S&P 500   4,076.57
DOW   34,395.01
QQQ   293.72
Is Apple Going To Rally Into Year End?
The Small Biotech Scaring Big Pharma (Ad)
25 Ways to Improve Your Financial Situation in 1 Hour
La-Z-Boy Reclines To More Comfortable Levels 
5 Hypergrowth Stocks to Own in 2023 (Ad)pixel
Are the Short Sellers Still Right About Mullen Automotive stock? 
Is The Recovery Rally Here For SoFi?
5 Hypergrowth Stocks to Own in 2023 (Ad)pixel
Biden administration presses senators to avert rail strike
Trump Org. defense lawyer scolded for using struck testimony
S&P 500   4,076.57
DOW   34,395.01
QQQ   293.72
Is Apple Going To Rally Into Year End?
The Small Biotech Scaring Big Pharma (Ad)
25 Ways to Improve Your Financial Situation in 1 Hour
La-Z-Boy Reclines To More Comfortable Levels 
5 Hypergrowth Stocks to Own in 2023 (Ad)pixel
Are the Short Sellers Still Right About Mullen Automotive stock? 
Is The Recovery Rally Here For SoFi?
5 Hypergrowth Stocks to Own in 2023 (Ad)pixel
Biden administration presses senators to avert rail strike
Trump Org. defense lawyer scolded for using struck testimony
S&P 500   4,076.57
DOW   34,395.01
QQQ   293.72
Is Apple Going To Rally Into Year End?
The Small Biotech Scaring Big Pharma (Ad)
25 Ways to Improve Your Financial Situation in 1 Hour
La-Z-Boy Reclines To More Comfortable Levels 
5 Hypergrowth Stocks to Own in 2023 (Ad)pixel
Are the Short Sellers Still Right About Mullen Automotive stock? 
Is The Recovery Rally Here For SoFi?
5 Hypergrowth Stocks to Own in 2023 (Ad)pixel
Biden administration presses senators to avert rail strike
Trump Org. defense lawyer scolded for using struck testimony
TSE:APS

Aptose Biosciences - APS Stock Forecast, Price & News

C$0.90
0.00 (0.00%)
(As of 12/1/2022 12:00 AM ET)
Add
Compare
Today's Range
C$0.90
C$0.91
50-Day Range
C$0.63
C$1.03
52-Week Range
C$0.62
C$2.73
Volume
6,296 shs
Average Volume
26,681 shs
Market Capitalization
C$83.07 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
C$8.50

Aptose Biosciences MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
844.4% Upside
C$8.50 Price Target
Short Interest
N/A
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
Acquiring Shares
C$5,025 Bought Last Quarter
Proj. Earnings Growth
N/A

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.59 out of 5 stars

APS stock logo

About Aptose Biosciences (TSE:APS) Stock

Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies. The company has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806, a non-covalent small molecule therapeutic agent, which is in preclinical stage for the treatment of acute myeloid leukemia and chronic lymphocytic leukemia/mantle cell lymphoma. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was founded in 1986 and is headquartered in Mississauga, Canada.

Receive APS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aptose Biosciences and its competitors with MarketBeat's FREE daily newsletter.

APS Stock News Headlines

Seagen (SGEN) Inks Deal With LAVA Therapeutics for LAVA-1223
The single greatest medical breakthrough of all time?
We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.
Aptose Reports Results for the First Quarter 2022
Tiny $4 Company to “Steal” Billions From Tesla? 
A tiny $4 company has developed a new liquid battery that’s sending shockwaves through the energy industry. It’s at the center of a “breakthrough,” says The U.S. Department of Energy, that’s a “totally new approach to battery technology.” Powermag calls it part of the “trillion-dollar holy grail” of battery technology.
Aptose Reports Results for the Third Quarter 2021
Aptose Reports Results for the Second Quarter 2021
Were Hedge Funds Right About Cutera, Inc. (CUTR)?
See More Headlines
Receive APS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aptose Biosciences and its competitors with MarketBeat's FREE daily newsletter.

APS Company Calendar

Today
12/01/2022
Next Earnings (Estimated)
3/28/2023

Industry, Sector and Symbol

Industry
Biotechnology
Sub-Industry
N/A
Sector
Medical
CIK
N/A
Fax
N/A
Employees
31
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
C$8.50
High Stock Price Forecast
C$12.00
Low Stock Price Forecast
C$5.00
Forecasted Upside/Downside
+844.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Cash Flow
C$0.59 per share
Book Value
C$0.51 per share

Miscellaneous

Free Float
N/A
Market Cap
C$83.07 million
Optionable
Not Optionable
Beta
N/A

Key Executives

  • Dr. William G. Rice Ph.D. (Age 59)
    Chairman, Pres & CEO
  • Mr. Gregory K. Chow CPA (Age 45)
    MBA, BA, Sr. VP, CFO & Principal Accounting Officer
  • Mr. Ernest Kitt B.S.
    M.S, VP of Devel. & Technical Operations
  • Dr. Stephen B. Howell (Age 73)
    Chief Medical Officer
  • Mr. Peter Murray
    Director of Clinical Devel.













APS Stock - Frequently Asked Questions

Should I buy or sell Aptose Biosciences stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Aptose Biosciences in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" APS shares.
View APS analyst ratings
or view top-rated stocks.

What is Aptose Biosciences' stock price forecast for 2023?

3 analysts have issued 12 month price objectives for Aptose Biosciences' stock. Their APS share price forecasts range from C$5.00 to C$12.00. On average, they predict the company's stock price to reach C$8.50 in the next year. This suggests a possible upside of 844.4% from the stock's current price.
View analysts price targets for APS
or view top-rated stocks among Wall Street analysts.

How have APS shares performed in 2022?

Aptose Biosciences' stock was trading at C$1.73 on January 1st, 2022. Since then, APS stock has decreased by 48.0% and is now trading at C$0.90.
View the best growth stocks for 2022 here
.

When is Aptose Biosciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 28th 2023.
View our APS earnings forecast
.

What other stocks do shareholders of Aptose Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Aptose Biosciences investors own include Aptose Biosciences (APTO), Aurinia Pharmaceuticals (AUPH), Advanced Micro Devices (AMD), NVIDIA (NVDA), Aurora Cannabis (ACB), Adobe (ADBE), AltaGas (ALA), Aphria (APHA), Algonquin Power & Utilities (AQN) and Badger Daylighting (BAD).

What is Aptose Biosciences' stock symbol?

Aptose Biosciences trades on the Toronto Stock Exchange (TSX) under the ticker symbol "APS."

How do I buy shares of Aptose Biosciences?

Shares of APS stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.

What is Aptose Biosciences' stock price today?

One share of APS stock can currently be purchased for approximately C$0.90.

How much money does Aptose Biosciences make?

Aptose Biosciences (TSE:APS) has a market capitalization of C$83.07 million.

How can I contact Aptose Biosciences?

Aptose Biosciences' mailing address is 5955 Airport Rd Suite 228, MISSISSAUGA, ON L4V 1R9, Canada. The official website for the company is aptose.com. The biotechnology company can be reached via phone at +1-647-4799828.

This page (TSE:APS) was last updated on 12/2/2022 by MarketBeat.com Staff